About Scantox
Scantox is a company based in Lille Skensved (Denmark) founded in 1977. Scantox has raised $6.29 million across 2 funding rounds. The company has 30 employees as of November 30, 2024. Scantox has completed 4 acquisitions, including Adlego Biomedical, Gentronix and Q&Q Labs. Scantox offers products and services including Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services. Scantox operates in a competitive market with competitors including Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
- Headquarter Lille Skensved, Denmark
- Employees 30 as on 30 Nov, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scantox Holding Aps
-
Annual Revenue
$18.22 M (USD)166as on Dec 31, 2022
-
Net Profit
$1.16 M (USD)71as on Dec 31, 2022
-
EBITDA
$1.45 M (USD)282as on Dec 31, 2022
-
Total Equity Funding
$6.29 M (USD)
in 2 rounds
-
Latest Funding Round
$228.85 K (USD), Unspecified
Jan 24, 2022
-
Investors
Not available
-
Employee Count
30
as on Nov 30, 2024
-
Investments & Acquisitions
Adlego Biomedical
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scantox
Scantox offers a comprehensive portfolio of products and services, including Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services.
Specialized services for neurology-related drug discovery and efficacy testing.
Comprehensive portfolio for genotoxicity and skin sensitization assessments.
Full spectrum of preclinical toxicology studies using various species.
Formulation development and bioanalysis for clinical trial support.
People of Scantox
Unlock access to complete
Unlock access to complete
Funding Insights of Scantox
Scantox has successfully raised a total of $6.29M across 2 strategic funding rounds. The most recent funding activity was a Unspecified round of $228.85 thousand completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Scantox
Scantox has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Adlego Biomedical, Gentronix and Q&Q Labs.
Investment portfolio details for Scantox
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drug R&D services for toxicology and histopathology are offered.
|
Locked | Locked | 2013 | Locked | |
|
Leading provider of preclinical services for the pharmaceutical, biotech, and medical devices industries
|
Locked | Locked | 2010 | Locked | |
|
In-vivo pharmacology and toxicology services are provided for drug candidates.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Scantox
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Scantox
Detailed financials for Scantox
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scantox Comparisons
Peer comparison for Scantox
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scantox
Scantox operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of drug discovery and preclinical development services
|
|
| Locked | Locked | Locked |
Provider of laboratory tests for physicians
|
|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
Provider of clinical research, development, and commercialization services for life sciences
|
|
| Locked | Locked | Locked |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare.
|
|
| Locked | Locked | Locked |
Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices
|
Detailed competitors of Scantox
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scantox
Complete news archive for Scantox
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scantox
Scantox was founded in 1977 and raised its 1st funding round 44 years after it was founded.
Scantox is headquartered in Lille Skensved, Denmark.
Jeanet Logsted is the current CEO of Scantox.
Scantox is a funded company, having raised a total of $6.29M across 2 funding rounds to date.
As of Nov 30, 2024, the latest employee count at Scantox is 30.
Annual revenue of Scantox is $18.22M as on Dec 31, 2022.
Scantox offers Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, Pharmaceutical Development Services while focusing on providing healthcare solutions, biopharma outsourcing, cro, and diversified. Laboratory focused on providing pharmacology, toxicology, and histopathology services. Delivering reliable solutions, it emphasizes quality, efficiency, and meeting diverse client needs.
Scantox's top competitors include LabCorp, Charles River Laboratories and Cytel.
Scantox offers Discovery Services, Genetic Toxicology Services, Regulatory Toxicology Services, and Pharmaceutical Development Services.
Scantox has made 4 acquisitions, including Adlego Biomedical, Gentronix, and Q&Q Labs.
The valuation of Scantox is $19.19M as of Jan 2022.